Literature DB >> 23146357

Coverage of blood vessels by astrocytic endfeet is reduced in major depressive disorder.

Grazyna Rajkowska1, Jonathan Hughes, Craig A Stockmeier, Jose Javier Miguel-Hidalgo, Dorota Maciag.   

Abstract

BACKGROUND: Depression and cerebrovascular disease influence each other, according to clinical studies. Despite this evidence, no studies have investigated the relationship between major depressive disorder (MDD) and cerebrovascular disease at the cellular level. Astrocytic processes are a crucial interface between blood vessels and neurons, and astrocyte density is reduced in MDD. This study investigated the coverage of vessels by astrocyte endfeet in the prefrontal cortex in MDD.
METHODS: Thirteen pairs of MDD and nonpsychiatric control subjects were used for double immunofluorescent staining and confocal image analysis. Frozen sections of gray matter from orbitofrontal area 47 and white matter from the ventromedial prefrontal cortex were examined. Astrocytic processes (labeled with antibodies for aquaporin-4 (AQP4) or glial fibrillary acidic protein were co-localized with blood vessels (labeled with an antibody to collagen IV) to measure the coverage of vessel walls by astrocyte processes.
RESULTS: The coverage of blood vessels by endfeet of AQP4-immunoreactive (IR) astrocytes was significantly reduced by 50% in subjects with MDD as compared with control subjects [analysis of covariance: F(1,23) = 5.161, p = .033]. This difference was detected in orbitofrontal gray matter but not in white matter. Conversely, the coverage of vessels by glial fibrillary acidic protein-IR processes did not significantly differ between the groups.
CONCLUSIONS: A significant reduction in the coverage of gray matter vessels by AQP4-IR astrocyte processes in MDD suggests alterations in AQP4 functions such as regulation of water homeostasis, blood flow, glucose transport and metabolism, the blood-brain barrier, glutamate turnover, and synaptic plasticity.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23146357      PMCID: PMC3578083          DOI: 10.1016/j.biopsych.2012.09.024

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  78 in total

1.  3-D cytoarchitectonic parcellation of human orbitofrontal cortex correlation with postmortem MRI.

Authors:  Harry B M Uylings; Ernesto J Sanz-Arigita; Koos de Vos; Chris W Pool; Paul Evers; Grazyna Rajkowska
Journal:  Psychiatry Res       Date:  2010-06-09       Impact factor: 3.222

Review 2.  Astrocyte-endothelial interactions at the blood-brain barrier.

Authors:  N Joan Abbott; Lars Rönnbäck; Elisabeth Hansson
Journal:  Nat Rev Neurosci       Date:  2006-01       Impact factor: 34.870

3.  Impaired endothelial function in coronary heart disease patients with depressive symptomatology.

Authors:  Andrew Sherwood; Alan L Hinderliter; Lana L Watkins; Robert A Waugh; James A Blumenthal
Journal:  J Am Coll Cardiol       Date:  2005-08-16       Impact factor: 24.094

4.  Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients.

Authors:  Grazyna Rajkowska; Jose Javier Miguel-Hidalgo; Priti Dubey; Craig A Stockmeier; K Ranga Rama Krishnan
Journal:  Biol Psychiatry       Date:  2005-08-15       Impact factor: 13.382

5.  Chronic cholinergic imbalances promote brain diffusion and transport abnormalities.

Authors:  Eran Meshorer; Inbal E Biton; Yoram Ben-Shaul; Shani Ben-Ari; Yaniv Assaf; Hermona Soreq; Yoram Cohen
Journal:  FASEB J       Date:  2005-06       Impact factor: 5.191

Review 6.  Neurobarrier coupling in the brain: a partner of neurovascular and neurometabolic coupling?

Authors:  Luc Leybaert
Journal:  J Cereb Blood Flow Metab       Date:  2005-01       Impact factor: 6.200

7.  Reliability of psychiatric diagnosis in postmortem research.

Authors:  Amy Deep-Soboslay; Mayada Akil; Catherine E Martin; Llewelyn B Bigelow; Mary M Herman; Thomas M Hyde; Joel E Kleinman
Journal:  Biol Psychiatry       Date:  2005-01-01       Impact factor: 13.382

Review 8.  Mineralocorticoid receptors: distribution and activation.

Authors:  John W Funder
Journal:  Heart Fail Rev       Date:  2005-01       Impact factor: 4.214

9.  Depression-executive dysfunction syndrome in stroke patients.

Authors:  Risto Vataja; Tarja Pohjasvaara; Riitta Mäntylä; Raija Ylikoski; Maarit Leskelä; Hely Kalska; Marja Hietanen; Hannu Juhani Aronen; Oili Salonen; Markku Kaste; Antero Leppävuori; Timo Erkinjuntti
Journal:  Am J Geriatr Psychiatry       Date:  2005-02       Impact factor: 4.105

10.  Sex- and region-specific alterations of basal amino acid and monoamine metabolism in the brain of aquaporin-4 knockout mice.

Authors:  Yi Fan; Jing Zhang; Xiu-Lan Sun; Lin Gao; Xiao-Ning Zeng; Jian-Hua Ding; Cong Cao; Ling Niu; Gang Hu
Journal:  J Neurosci Res       Date:  2005-11-15       Impact factor: 4.164

View more
  50 in total

Review 1.  Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Authors:  Mark J Niciu; Ioline D Henter; Gerard Sanacora; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-12       Impact factor: 4.132

2.  Oligodendrocyte morphometry and expression of myelin - Related mRNA in ventral prefrontal white matter in major depressive disorder.

Authors:  Grazyna Rajkowska; Gouri Mahajan; Dorota Maciag; Monica Sathyanesan; Abiye H Iyo; Mohadetheh Moulana; Patrick B Kyle; William L Woolverton; Jose Javier Miguel-Hidalgo; Craig A Stockmeier; Samuel S Newton
Journal:  J Psychiatr Res       Date:  2015-04-20       Impact factor: 4.791

3.  Evidence of decreased gap junction coupling between astrocytes and oligodendrocytes in the anterior cingulate cortex of depressed suicides.

Authors:  Arnaud Tanti; Pierre-Eric Lutz; John Kim; Liam O'Leary; Jean-François Théroux; Gustavo Turecki; Naguib Mechawar
Journal:  Neuropsychopharmacology       Date:  2019-08-02       Impact factor: 7.853

Review 4.  Pharmacological modulation of astrocytes and the role of cell type-specific histone modifications for the treatment of mood disorders.

Authors:  Mira Jakovcevski; Schahram Akbarian; Barbara Di Benedetto
Journal:  Curr Opin Pharmacol       Date:  2015-10-26       Impact factor: 5.547

5.  Ischemic neurons activate astrocytes to disrupt endothelial barrier via increasing VEGF expression.

Authors:  Ying-Na Li; Rong Pan; Xu-Jun Qin; Wei-Lin Yang; Zhifeng Qi; Wenlan Liu; Ke Jian Liu
Journal:  J Neurochem       Date:  2013-12-06       Impact factor: 5.372

Review 6.  Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Erica M Richards; Carlos A Zarate
Journal:  J Neural Transm (Vienna)       Date:  2013-12-08       Impact factor: 3.575

7.  Evidence that neurovascular coupling underlying the BOLD effect increases with age during childhood.

Authors:  Vincent J Schmithorst; Jennifer Vannest; Gregory Lee; Luis Hernandez-Garcia; Elena Plante; Akila Rajagopal; Scott K Holland
Journal:  Hum Brain Mapp       Date:  2014-08-19       Impact factor: 5.038

8.  Chronic stress impairs the aquaporin-4-mediated glymphatic transport through glucocorticoid signaling.

Authors:  Fang Wei; Jian Song; Cui Zhang; Jun Lin; Rong Xue; Li-Dong Shan; Shan Gong; Guo-Xing Zhang; Zheng-Hong Qin; Guang-Yin Xu; Lin-Hui Wang
Journal:  Psychopharmacology (Berl)       Date:  2019-01-03       Impact factor: 4.530

Review 9.  Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities.

Authors:  Madeline L Pfau; Caroline Ménard; Scott J Russo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-10-06       Impact factor: 13.820

10.  Effects of fish oil supplementation on prefrontal metabolite concentrations in adolescents with major depressive disorder: a preliminary 1H MRS study.

Authors:  Robert K McNamara; Ronald Jandacek; Therese Rider; Patrick Tso; Wen-Jang Chu; Wade A Weber; Jeffrey A Welge; Jeffrey R Strawn; Caleb M Adler; Melissa P DelBello
Journal:  Nutr Neurosci       Date:  2016-03-02       Impact factor: 4.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.